49 related articles for article (PubMed ID: 38335435)
21. Development of an Immune-Related Prognostic Signature in Breast Cancer.
Xie P; Ma Y; Yu S; An R; He J; Zhang H
Front Genet; 2019; 10():1390. PubMed ID: 32047513
[TBL] [Abstract][Full Text] [Related]
22. First-Line Treatment With Atezolizumab Plus Nab-Paclitaxel for Advanced Triple-Negative Breast Cancer: A Cost-Effectiveness Analysis.
Weng X; Huang X; Li H; Lin S; Rao X; Guo X; Huang P
Am J Clin Oncol; 2020 May; 43(5):340-348. PubMed ID: 32028340
[TBL] [Abstract][Full Text] [Related]
23. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Schmid P; Rugo HS; Adams S; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Henschel V; Molinero L; Chui SY; Maiya V; Husain A; Winer EP; Loi S; Emens LA;
Lancet Oncol; 2020 Jan; 21(1):44-59. PubMed ID: 31786121
[TBL] [Abstract][Full Text] [Related]
24. Prognostic nomogram based on immune scores for breast cancer patients.
Wang J; Li Y; Fu W; Zhang Y; Jiang J; Zhang Y; Qi X
Cancer Med; 2019 Sep; 8(11):5214-5222. PubMed ID: 31342666
[TBL] [Abstract][Full Text] [Related]
25. Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: Update of the ASCO Endorsement of the Cancer Care Ontario Guideline.
Henry NL; Somerfield MR; Abramson VG; Ismaila N; Allison KH; Anders CK; Chingos DT; Eisen A; Ferrari BL; Openshaw TH; Spears PA; Vikas P; Stearns V
J Clin Oncol; 2019 Aug; 37(22):1965-1977. PubMed ID: 31206315
[TBL] [Abstract][Full Text] [Related]
26. Contrasting Epidemiology and Clinicopathology of Female Breast Cancer in Asians vs the US Population.
Lin CH; Yap YS; Lee KH; Im SA; Naito Y; Yeo W; Ueno T; Kwong A; Li H; Huang SM; Leung R; Han W; Tan B; Hu FC; Huang CS; Cheng AL; Lu YS;
J Natl Cancer Inst; 2019 Dec; 111(12):1298-1306. PubMed ID: 31093668
[TBL] [Abstract][Full Text] [Related]
27. Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies.
Jiang YZ; Ma D; Suo C; Shi J; Xue M; Hu X; Xiao Y; Yu KD; Liu YR; Yu Y; Zheng Y; Li X; Zhang C; Hu P; Zhang J; Hua Q; Zhang J; Hou W; Ren L; Bao D; Li B; Yang J; Yao L; Zuo WJ; Zhao S; Gong Y; Ren YX; Zhao YX; Yang YS; Niu Z; Cao ZG; Stover DG; Verschraegen C; Kaklamani V; Daemen A; Benson JR; Takabe K; Bai F; Li DQ; Wang P; Shi L; Huang W; Shao ZM
Cancer Cell; 2019 Mar; 35(3):428-440.e5. PubMed ID: 30853353
[TBL] [Abstract][Full Text] [Related]
28. Multi-Omics Profiling Reveals Distinct Microenvironment Characterization and Suggests Immune Escape Mechanisms of Triple-Negative Breast Cancer.
Xiao Y; Ma D; Zhao S; Suo C; Shi J; Xue MZ; Ruan M; Wang H; Zhao J; Li Q; Wang P; Shi L; Yang WT; Huang W; Hu X; Yu KD; Huang S; Bertucci F; Jiang YZ; Shao ZM;
Clin Cancer Res; 2019 Aug; 25(16):5002-5014. PubMed ID: 30837276
[TBL] [Abstract][Full Text] [Related]
29. Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers.
Loi S; Drubay D; Adams S; Pruneri G; Francis PA; Lacroix-Triki M; Joensuu H; Dieci MV; Badve S; Demaria S; Gray R; Munzone E; Lemonnier J; Sotiriou C; Piccart MJ; Kellokumpu-Lehtinen PL; Vingiani A; Gray K; Andre F; Denkert C; Salgado R; Michiels S
J Clin Oncol; 2019 Mar; 37(7):559-569. PubMed ID: 30650045
[TBL] [Abstract][Full Text] [Related]
30. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study.
Adams S; Schmid P; Rugo HS; Winer EP; Loirat D; Awada A; Cescon DW; Iwata H; Campone M; Nanda R; Hui R; Curigliano G; Toppmeyer D; O'Shaughnessy J; Loi S; Paluch-Shimon S; Tan AR; Card D; Zhao J; Karantza V; Cortés J
Ann Oncol; 2019 Mar; 30(3):397-404. PubMed ID: 30475950
[TBL] [Abstract][Full Text] [Related]
31. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study.
Adams S; Loi S; Toppmeyer D; Cescon DW; De Laurentiis M; Nanda R; Winer EP; Mukai H; Tamura K; Armstrong A; Liu MC; Iwata H; Ryvo L; Wimberger P; Rugo HS; Tan AR; Jia L; Ding Y; Karantza V; Schmid P
Ann Oncol; 2019 Mar; 30(3):405-411. PubMed ID: 30475947
[TBL] [Abstract][Full Text] [Related]
32. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.
Schmid P; Adams S; Rugo HS; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Hegg R; Im SA; Shaw Wright G; Henschel V; Molinero L; Chui SY; Funke R; Husain A; Winer EP; Loi S; Emens LA;
N Engl J Med; 2018 Nov; 379(22):2108-2121. PubMed ID: 30345906
[TBL] [Abstract][Full Text] [Related]
33. Multi-omics profiling of younger Asian breast cancers reveals distinctive molecular signatures.
Kan Z; Ding Y; Kim J; Jung HH; Chung W; Lal S; Cho S; Fernandez-Banet J; Lee SK; Kim SW; Lee JE; Choi YL; Deng S; Kim JY; Ahn JS; Sha Y; Mu XJ; Nam JY; Im YH; Lee S; Park WY; Nam SJ; Park YH
Nat Commun; 2018 Apr; 9(1):1725. PubMed ID: 29713003
[TBL] [Abstract][Full Text] [Related]
34. A tumor-myeloid cell axis, mediated via the cytokines IL-1α and TSLP, promotes the progression of breast cancer.
Kuan EL; Ziegler SF
Nat Immunol; 2018 Apr; 19(4):366-374. PubMed ID: 29556001
[TBL] [Abstract][Full Text] [Related]
35. Cistrome Cancer: A Web Resource for Integrative Gene Regulation Modeling in Cancer.
Mei S; Meyer CA; Zheng R; Qin Q; Wu Q; Jiang P; Li B; Shi X; Wang B; Fan J; Shih C; Brown M; Zang C; Liu XS
Cancer Res; 2017 Nov; 77(21):e19-e22. PubMed ID: 29092931
[TBL] [Abstract][Full Text] [Related]
36. Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade.
Charoentong P; Finotello F; Angelova M; Mayer C; Efremova M; Rieder D; Hackl H; Trajanoski Z
Cell Rep; 2017 Jan; 18(1):248-262. PubMed ID: 28052254
[TBL] [Abstract][Full Text] [Related]
37. Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study.
Luen SJ; Salgado R; Fox S; Savas P; Eng-Wong J; Clark E; Kiermaier A; Swain SM; Baselga J; Michiels S; Loi S
Lancet Oncol; 2017 Jan; 18(1):52-62. PubMed ID: 27964843
[TBL] [Abstract][Full Text] [Related]
38. Patterns of Immune Infiltration in Breast Cancer and Their Clinical Implications: A Gene-Expression-Based Retrospective Study.
Ali HR; Chlon L; Pharoah PD; Markowetz F; Caldas C
PLoS Med; 2016 Dec; 13(12):e1002194. PubMed ID: 27959923
[TBL] [Abstract][Full Text] [Related]
39. Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma.
Hugo W; Zaretsky JM; Sun L; Song C; Moreno BH; Hu-Lieskovan S; Berent-Maoz B; Pang J; Chmielowski B; Cherry G; Seja E; Lomeli S; Kong X; Kelley MC; Sosman JA; Johnson DB; Ribas A; Lo RS
Cell; 2016 Mar; 165(1):35-44. PubMed ID: 26997480
[TBL] [Abstract][Full Text] [Related]
40. Thymic stromal lymphopoietin blocks early stages of breast carcinogenesis.
Demehri S; Cunningham TJ; Manivasagam S; Ngo KH; Moradi Tuchayi S; Reddy R; Meyers MA; DeNardo DG; Yokoyama WM
J Clin Invest; 2016 Apr; 126(4):1458-70. PubMed ID: 26927668
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
